Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation

被引:33
|
作者
Patel, P. [1 ,2 ,3 ]
Gupta, P. K. C. [1 ,2 ,3 ]
White, C. M. J. [2 ,4 ]
Stanley, A. G. [4 ]
Williams, B. [5 ,6 ]
Tomaszewski, M. [2 ,3 ,4 ]
机构
[1] Univ Hosp Leicester NHS Trust, Dept Metab Med & Chem Pathol, Leicester, Leics, England
[2] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England
[3] Glenfield Gen Hosp, NIHR Leicester Cardiovasc Biomed Res Unit, Leicester LE3 9QP, Leics, England
[4] Univ Hosp Leicester NHS Trust, Leicester, Leics, England
[5] UCL, Inst Cardiovasc Sci, London, England
[6] Univ Coll London Hosp, Biomed Res Ctr, NIHR, London, England
基金
英国医学研究理事会;
关键词
TREATMENT-RESISTANT HYPERTENSION; SYMPATHETIC DENERVATION; ADHERENCE; URINE; ELIGIBILITY; MEDICATION; TRIAL; DRUGS;
D O I
10.1038/jhh.2015.103
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Renal denervation is a potential therapeutic option for resistant hypertension. A thorough clinical assessment to exclude reversible/spurious causes of resistance to antihypertensive therapy is required prior to this procedure. The extent to which non-adherence to antihypertensive treatment contributes to apparent resistance to antihypertensive therapy in patients considered for renal denervation is not known. Patients (n = 34) referred for renal denervation entered the evaluation pathway that included screening for adherence to antihypertensive treatment by high-performance liquid chromatography-tandem mass spectrometry-based urine analysis. Biochemical non-adherence to antihypertensive treatment was the most common cause of non-eligibility for renal denervation-23.5% of patients were either partially or completely non-adherent to prescribed antihypertensive treatment. About 5.9% of those referred for renal denervation had admitted non-adherence prior to performing the screening test. Suboptimal pharmacological treatment of hypertension and 'white-coat effect' accounted for apparently resistant hypertension in a further 17.7 and 5.9% of patients, respectively. Taken together, these three causes of pseudo-resistant hypertension accounted for 52.9% of patients referred for renal denervation. Only 14.7% of referred patients were ultimately deemed eligible for renal denervation. Without biochemical screening for therapeutic non-adherence, the eligibility rate for renal denervation would have been 38.2%. Non-adherence to antihypertensive treatment and other forms of therapeutic pseudo-resistance are by far the most common reason of 'resistant hypertension' in patients referred for renal denervation. We suggest that inclusion of biochemical screening for non-adherence to antihypertensive treatment may be helpful in evaluation of patients with 'resistant hypertension' prior to consideration of renal denervation.
引用
收藏
页码:368 / 373
页数:6
相关论文
共 50 条
  • [21] Impact of Non-Adherence on Renal and Cardiovascular Outcomes in US Veterans
    Gosmanova, Elvira O.
    Molnar, Miklos Z.
    Alrifai, Ahmed
    Lu, Jun L.
    Streja, Elani
    Cushman, William C.
    Kalantar-Zadeh, Kamyar
    Kovesdy, Csaba P.
    AMERICAN JOURNAL OF NEPHROLOGY, 2015, 42 (02) : 151 - 157
  • [22] Prediction of high risk of non-adherence to antiplatelet treatment
    Kubica, Aldona
    Obonska, Karolina
    Kasprzak, Michal
    Sztuba, Beata
    Navarese, Eliano Pio
    Kozinski, Marek
    Swiatkiewicz, Iwona
    Kieszkowska, Magdalena
    Ostrowska, Malgorzata
    Grzesk, Grzegorz
    Kubica, Jacek
    KARDIOLOGIA POLSKA, 2016, 74 (01) : 61 - 67
  • [23] Evaluation of non-adherence to hipoglucemiary treatment in community pharmacy
    Leites-Docio, Andrea
    Garcia-Rodriguez, Patricia
    Fernandez-Cordeiro, Marta
    Tenorio-Salgueiro, Lorena
    Fornos-Perez, Jose A.
    Floro Andres-Rodriguez, N.
    FARMACEUTICOS COMUNITARIOS, 2019, 11 (01): : 5 - 13
  • [24] Adverse effects and non-adherence to antihypertensive medications in University of Gondar Comprehensive Specialized Hospital
    Eyob Alemayehu Gebreyohannes
    Akshaya Srikanth Bhagavathula
    Tamrat Befekadu Abebe
    Yonas Getaye Tefera
    Tadesse Melaku Abegaz
    Clinical Hypertension, 25
  • [25] Prevalence of non-adherence to antihypertensive medication in Asia: a systematic review and meta-analysis
    Mahmood, Sajid
    Jalal, Zahraa
    Hadi, Muhammad Abdul
    Khan, Tahir Mehmood
    Haque, M. Sayeed
    Shah, Kifayat Ullah
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (03) : 486 - 501
  • [26] Adverse effects and non-adherence to antihypertensive medications in University of Gondar Comprehensive Specialized Hospital
    Gebreyohannes, Eyob Alemayehu
    Bhagavathula, Akshaya Srikanth
    Abebe, Tamrat Befekadu
    Tefera, Yonas Getaye
    Abegaz, Tadesse Melaku
    CLINICAL HYPERTENSION, 2019, 25 (01)
  • [27] Non-adherence to antihypertensive medications in Lebanese adults hospitalized for hypertensive urgency and its cost
    Abbas, Hanine
    Hallit, Souheil
    Kurdi, Mazen
    Karam, Rita
    BMC CARDIOVASCULAR DISORDERS, 2022, 22 (01)
  • [28] Impact of renal denervation on quality of life how does renal denervation contribute to improving hypertension treatment affected by poor medication adherence?
    Okamura, Keisuke
    Shimada, Hideaki
    Imazato, Keisuke
    Sako, Hideto
    Udo, Akihiro
    Taniguchi, Kenichiro
    Morisaki, Shogo
    Imamura, Ichiro
    Urata, Hidenori
    Arima, Hisatomi
    Miura, Shin-ichiro
    HYPERTENSION RESEARCH, 2024, 47 (10) : 2652 - 2658
  • [29] Structural and Social Determinants of Health Factors Associated with County-Level Variation in Non-Adherence to Antihypertensive Medication Treatment
    Donneyong, Macarius M.
    Chang, Teng-Jen
    Jackson, John W.
    Langston, Michael A.
    Juarez, Paul D.
    Sealy-Jefferson, Shawnita
    Lu, Bo
    Im, Wansoo
    Valdez, R. Burciaga
    Way, Baldwin M.
    Colen, Cynthia
    Fischer, Michael A.
    Salsberry, Pamela
    Bridges, John F. P.
    Hood, Darryl B.
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (18) : 1 - 12
  • [30] Systematic review: non-adherence and non-persistence in intravitreal treatment
    Ehlken, Christoph
    Ziemssen, Focke
    Eter, Nicole
    Lanzl, Ines
    Kaymak, Hakan
    Lommatzsch, Albrecht
    Schuster, Alexander K.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2020, 258 (10) : 2077 - 2090